TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Drug Store News2d
FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology
Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...
Daily3d
Roche gets USFDA nod for Ocrevus Zunovo for relapsing and progressive multiple sclerosis
Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...
MedPage Today4d
Brain Training and Memory Decline; Alzheimer's Pioneer Dies; Notorious APOE4
Subcutaneous ocrelizumab and hyaluronidase (Ocrevus Zunovo) was approved for relapsing and progressive multiple sclerosis, ...
The American Journal of Managed Care5d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Pharmabiz5d
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
Pharmaceutical Technology6d
Disease modifiers may take over PAH landscape, says Cereno CEO
As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
The Pharma Letter6d
Roche scores first, with FDA approval of Ocrevus Zunovo for MS
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment ...
Managed Healthcare Executive6d
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...
kalkinemedia6d
Abbott Laboratories' Top Segment Enhances Performance
Abbott Laboratories,(NYSE: ABT),has experienced a dynamic few years, navigating significant disruptions and shifting market ...